February 16, 2006
Humanetics Corp Expands Dept Of Defense (DOD) Relationships With Response to Request from Missle & Space Command.
Response to SSN Opens Door for Humanetics to Additional Research Arm of DoD
Minneapolis, MN, February 16, 2006-- Moving quickly to extend its active collaboration with the U.S. Department of Defense (DoD), Humanetics Corporation said today that it has responded to a request for information under a Sources Sought Notice (SSN) for viable radiation sickness countermeasures issued by the U.S. Army Space and Missile Defense Command. This represents the third research arm of the DoD with which Humanetics has a relationship.
The stated purpose of the SSN is to identify companies that believe they have viable candidate drugs that can be quickly developed as safe and effective countermeasures against radiation injury.
"We are confident that Humanetics. current track record of success with the DoD will be an important consideration in evaluating the potential efficacy of our countermeasure candidates," said Ronald Zenk, President and CEO of Humanetics. "We have worked collaboratively with Defense for more than two years.and our work is further supported by a Congressional appropriation," he added. Recently, Humanetics elected General Richard I. Neal, the former Assistant Commandant of the U.S. Marine Corps, to its Board of Directors. General Neal has extensive private sector experience working with defenserelated companies, helping to navigate the complexities of working with the DoD.
Humanetics is currently involved in collaborative research with the Armed Forces Radiology Research Institute (AFRRI), a research institute within the Uniformed Services University of the Health Sciences (USU), a fully accredited graduate education university within the DoD, to develop safe, effective, low-cost oral countermeasures to prevent acute radiation sickness (ARS). In January, Humanetics received a $1.25 million federal grant from the DoD.s 2006 Appropriations Budget to further develop ARS countermeasures. To date, the Company has identified two potentially effective agents, BIO 300 and BIO 500, both of which have been proven effective in animal models.
Humanetics has also entered into three Cooperative Research and Development Agreements (CRADA) with two DoD research groups. One of these agreements is a "
Multi-Project CRADA" for ongoing development of a pipeline of candidate compounds. Over the past two years, Humanetics has successfully collaborated with USU/AFRRI and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), a private, not-for-profit organization authorized by Congress to support medical education and research at USU and throughout the military medical community, in developing two leading oral countermeasure candidates for ARS. Data on these oral agents was submitted January 31, 2006 as part of the .Submission for the Sources Sought Notice. issued by the U.S. Army Space & Missile Defense Command.
Humanetics intends to complete pre-clinical work on both agents within the next few months. Following that, the Company said it would move into efficacy studies and file an Investigational New Drug (IND) application for both agents in mid-2006 with the Food & Drug Administration.